Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Dose, Open Label, Uncontrolled, Safety Trial of Intravenous Administration of Idarucizumab to Paediatric Patients Enrolled From Ongoing Phase IIb/III Clinical Trials With Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism.

NCT02815670 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02815670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02815670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Dose, Open Label, Uncontrolled, Safety Trial of Intravenous Administration of Idarucizumab to Paediatric Patients Enrolled From Ongoing Phase IIb/III Clinical Trials With Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
September 7, 2016
Completion date
October 19, 2019
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hemorrhage